Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ms. Karah Herdman Parschauer J.D.

Chief Legal Officer & Executive Vice President of Corporate Affairs

Mr. Howard  Horn

Executive Vice President of Corporate Strategy & Chief Financial Officer

Mr. Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

Mr. Thomas R. Kassberg

Chief Business Officer & Executive Vice President

Mr. Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

Ms. Danielle  Keatley

Senior Director of Investor Relations & Corporate Communications

Mr. Vimal  Srivastava

Senior Vice President of Business Development & Alliance Management

Mr. Erik  Harris

Executive Vice President & Chief Commercial Officer

Mr. John Richard Pinion II

Chief Quality Operations Officer & Executive Vice President of Translational Sciences

Dr. Emil D. Kakkis M.D., Ph.D.

Founder, President, Chief Executive Officer & Director

Биотехнологии

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. Структура на управлението

Информация за управлението